US Food and Drug Administration Approves Pancreatic Cancer Drug

The US Food and Drug Administration (FDA) has approved daraxonrasib, a new pancreatic cancer treatment that nearly doubled patient survival time in clinical trials, marking a breakthrough step in one of the most deadly types of cancer.

Clinical Trial Results

In an advanced-stage clinical trial involving 500 patients, the average survival time for those who took the pill-form medication daily was determined to be 13.2 months.

In the same study, the average survival time for patients receiving chemotherapy was determined to remain at 6.6 months.

Mechanism of Action of the Drug

Daraxonrasib targets the mutated KRAS gene, which is found in more than 90 percent of pancreatic tumors and triggers cancer growth.

By disabling this gene, the drug helps prevent the cancer from spreading and offers a new option for difficult cases.

State of Pancreatic Cancer

According to American Cancer Society data, approximately 67,000 people are diagnosed with pancreatic cancer in the US each year.

This type of cancer has the highest mortality rate among all major cancers, with more than half of patients losing their lives within three months of diagnosis.

Early Approval Process

In 2025, the FDA had granted the drug breakthrough therapy status, which is applied in the treatment of serious conditions.

Due to the results seen in an area of unmet medical need, the agency provided approval six months early without waiting for the regulatory deadline to expire.

Side Effects and Experiences

The most common side effects of the treatment include skin rash, diarrhea, nausea, fatigue, and vomiting.

Former US Senator Ben Sasse was also among the patients who participated in the clinical trial, stating that the drug helped his tumors shrink.